Denali TherapeuticsDNLI
Recorded

Denali Therapeutics Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration27 minParticipants1

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Speaker

Yeah, thanks very much, everybody. Happy to be moderating this chat with Joe Lewcock, Chief Scientific Officer of Denali Therapeutics. I think we'll kick off and maybe hit a couple questions on the AVLAYAH launch and how that's all going. Then I think we'll use this as an opportunity to maybe do a deeper dive into each pipeline program and preview some of the data readouts next year. But yeah, thank you, Joe. So maybe to kick it off, do you want to just level set for people and review the updates you gave on AVLAYAH in the past quarter, and overall, how's that launch gone relative to your guys' expectations?

Joe LewcockChief Scientific Officer

Yeah. Thanks, Paul. Thanks for having us, by the way. Very excited about the AVLAYAH launch so far. Seeing a lot of strong interest in the product, and really what we're hearing from both patient families and KOLs is that the drug is really making an impact for patients, which is fantastic. It really takes patients and physicians and payers working together in order to have a strong launch like this, and that's exactly what we're seeing. So we have about 70% of commercial lives covered, with 20 states covering on Medicaid coverage at this point. So very encouraging start to date, and it's led to $7.8 million in commercial revenue in just the second quarter after launch, which is fantastic.

Speaker

Yeah, that's great. I think with Hunter, there's always been this kind of question around what percent of patients have meaningful CNS symptoms. How do you define that? With now being in the market for a bit, what are you seeing in terms of the way physicians are segmenting patients and sense of urgency to treat the ELAPRASE-treated population with this medicine?

Joe LewcockChief Scientific Officer

Yeah. We're seeing a strong level of interest, and I think our feeling is the majority of patients have some sort of neuropathic symptoms. Of course, we're targeting patients within our label, but really what we're hearing from KOLs is that it's making an impact across a broad patient population.

Speaker

Okay. Understanding that your label doesn't cover everybody on ELAPRASE, but for the overlapping population there, at this point, what do you think is a realistic goal in terms of penetrating that population? Do you think it's a goal to switch most patients eventually over time? What's kind of the thought process?

Joe LewcockChief Scientific Officer

Yeah. Our goal is to really switch 100% of eligible patients. So in the U.S., there's about 500 patients with Hunter's disease. About 375 of those are eligible under our label, and our eventual goal is to really pivot all of those patients over to AVLAYAH.

Speaker

Okay. You guys have been guiding each quarter for the next quarter. Maybe just talk about how you guys have set expectations for the next quarter, and just more broadly, what metrics or things might you share or might you not share, I guess, going into 2027? Do you have a sense of that?

Joe LewcockChief Scientific Officer

Yeah. In our first quarter, we had a pretty big leap from our first quarter or second quarter, from $3.6 million to $7.8 million. That was well ahead of what we had predicted. We had guided around $10 million-$12 million, and significantly beat that. The drivers of that were really faster expansion of payer coverage, and that was fantastic, but then also a number of patients from our clinical trials switching over more quickly than we had anticipated, which was great to see. So it was really rapid growth in the past quarter. But what we've described many times is that we expect somewhat of an S-shaped curve here, where we'll see a steep ramp-up at some point. I think what we saw was based on those factors I mentioned, that that S-shaped curve was pushed in a bit faster than we had thought.

Joe LewcockChief Scientific Officer

We are still expecting growth, but in a more measured way moving forward. We have guided for the fourth quarter to be between $30 million and $32 million in commercial revenue, and we think that that is going to be a more predictable number.

Speaker

Okay, great. You are also set to, I think, complete the confirmatory trial next year. I think from our perspective, I think it is pretty clear AVLAYAH works, given the heparan sulfate data and the neurofilament data, but there is always this risk of going from an open-label study to placebo-controlled on clinical and functional endpoints. Maybe talk about how that study is designed and your level of confidence that, in the absence of placebo-controlled data, you have powered that somewhat conservatively.

Joe LewcockChief Scientific Officer

Yeah. No, great question. We have a lot of confidence in the outcome of COMPASS, which we will get data next year and then hopefully file on it in 2028. The reason why is we have already had 47 patients of data as part of our phase I and phase II programs, so a really high number of patients. What we were able to do in that first study is not only show a biomarker readout, which was the basis for approval, but a lot of other behavioral and cognitive endpoints as well. We were able to use that data to power COMPASS in a way that we felt like we had a lot of confidence in. When we do go and file, we will file based on the entirety of the data.

Joe LewcockChief Scientific Officer

I think we have a high level of confidence we are going to be able to reproduce those results in a placebo-controlled fashion.

Speaker

Maybe more specifically on the actual primary outcome measure for COMPASS, what is your expectation for the placebo arm and how that might all play out?

Joe LewcockChief Scientific Officer

Yeah. I think that we have a good idea, we feel, of how that placebo is going to behave based on natural history data that's been out there, both from what we've used in our previous powering study. I think that, again, I think we can make some good predictions. With a rare disease, powering, getting enough patients to run that trial in a convincing fashion is always a challenge. But we've tried to really run a robust study, not just to understand the cognitive readouts, but then we also have a second part B of that study to look at other aspects, somatic aspects of disease. The hope is really that COMPASS will open us up to really the full patient population in Hunter's disease, including adults.

Speaker

Okay. That's reading out in the first half of 2028.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day